PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
ADMA Biologics, Inc. (ADMA)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINUS0008991046
CUSIP000899104
SectorHealthcare
IndustryBiotechnology

Highlights

Market Cap$1.44B
EPS-$0.13
Revenue (TTM)$258.22M
Gross Profit (TTM)$35.27M
EBITDA (TTM)$32.76M
Year Range$3.06 - $6.47
Target Price$8.00
Short %3.09%
Short Ratio3.05

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds to compare with ADMA

ADMA Biologics, Inc.

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in ADMA Biologics, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-50.00%0.00%50.00%100.00%150.00%200.00%OctoberNovemberDecember2024FebruaryMarch
-21.17%
202.83%
ADMA (ADMA Biologics, Inc.)
Benchmark (^GSPC)

S&P 500

Returns By Period

ADMA Biologics, Inc. had a return of 49.12% year-to-date (YTD) and 109.97% in the last 12 months. Over the past 10 years, ADMA Biologics, Inc. had an annualized return of -2.14%, while the S&P 500 had an annualized return of 10.96%, indicating that ADMA Biologics, Inc. did not perform as well as the benchmark.


PeriodReturnBenchmark
Year-To-Date49.12%10.04%
1 month24.81%3.53%
6 months87.74%22.79%
1 year109.97%32.16%
5 years (annualized)12.23%13.15%
10 years (annualized)-2.14%10.96%

Monthly Returns Heatmap


JanFebMarAprMayJunJulAugSepOctNovDec
202414.82%3.28%
2023-7.23%-7.01%-5.59%9.47%22.16%

Risk-Adjusted Performance

Risk-Adjusted Performance Indicators

This table presents risk-adjusted performance metrics for ADMA Biologics, Inc. (ADMA) and compares them with a selected benchmark (^GSPC). These performance indicators assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratioSortino ratioOmega ratioCalmar ratioUlcer Index
ADMA
ADMA Biologics, Inc.
2.37
^GSPC
S&P 500
2.76

Sharpe Ratio

The current ADMA Biologics, Inc. Sharpe ratio is 2.37. A Sharpe ratio higher than 2.0 is considered very good.


Rolling 12-month Sharpe Ratio0.000.501.001.502.002.503.00OctoberNovemberDecember2024FebruaryMarch
2.37
2.76
ADMA (ADMA Biologics, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


ADMA Biologics, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-80.00%-60.00%-40.00%-20.00%0.00%OctoberNovemberDecember2024FebruaryMarch
-46.08%
0
ADMA (ADMA Biologics, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the ADMA Biologics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the ADMA Biologics, Inc. was 91.28%, occurring on Oct 11, 2021. The portfolio has not yet recovered.

The current ADMA Biologics, Inc. drawdown is 46.08%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-91.28%Nov 7, 20141741Oct 11, 2021
-20.47%Oct 18, 201346Dec 23, 201317Jan 27, 201463
-18.89%Mar 4, 201440May 12, 201412Jun 3, 201452
-12.38%Jul 10, 201433Aug 27, 201425Oct 2, 201458
-6.81%Oct 7, 20141Oct 7, 20145Oct 14, 20146

Volatility

Volatility Chart

The current ADMA Biologics, Inc. volatility is 11.17%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


2.00%4.00%6.00%8.00%10.00%12.00%14.00%OctoberNovemberDecember2024FebruaryMarch
11.17%
2.82%
ADMA (ADMA Biologics, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of ADMA Biologics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM
Revenue

Total Revenue

0.00

Cost Of Revenue

0.00

Gross Profit

0.00
Operating Expenses

Selling, General & Admin Expenses

0.00

R&D Expenses

0.00

Total Operating Expenses

0.00
Income

Income Before Tax

0.00

Operating Income

0.00

EBIT

0.00

Earnings From Continuing Operations

0.00

Net Income

0.00

Income Tax Expense

0.00

Interest Expense

0.00

Other Non-Operating Income (Expenses)

0.00

Extraordinary Items

0.00

Discontinued Operations

0.00

Effect Of Accounting Charges

0.00

Non Recurring

0.00

Minority Interest

0.00

Other Items

0.00
Values in undefined except per share items